Vital Signs - Molecular Diagnostics... Concerns for Today and Tomorrow


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on April 14, 2008, provides an strategic overview of current molecular diagnostic tests and a discussion of future needs. Additionally, a company spotlight is provided for Nanosphere, an emerging nanotechnology based molecular diagnostics company. Reimbursement and regulatory news from the FDA is also provided for the week of March 31 - April 4, 2008.

Table of Contents

Vital Signs - Molecular Diagnostics... Concerns for Today and TomorrowVital Signs: 14 April 2008This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.